Regen BioPharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Regen BioPharma generated cash of -$693,141, which is less than the previous year. Cash used in financing activities reached the amount of $572,819 last year. Net change in cash is therefore -$120,322.
Cash Flow
| 2015 | -11.01M | 0 | 11.05M |
|---|---|---|---|
| 2016 | -1.67M | 0 | 1.65M |
| 2017 | -1.89M | 0 | 2.13M |
| 2018 | -1.57M | -5.74K | 1.32M |
| 2019 | -481.79K | 49.85K | 431.77K |
| 2020 | 18.64K | 0 | -26.5K |
| 2021 | -1.13M | 495K | 1.36M |
| 2022 | -606.92K | 25K | -94.03K |
| 2023 | -173.91K | 0 | 243.75K |
| 2024 | -693.14K | 0 | 572.81K |
RGBP Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 121.03K | 51.20K | 727.16K | 0 | 7.85K | 8.01K | 269.97K | 24.82K | 38.62K | 0 |
Operating activities | ||||||||||
Net income | -867.25K | 1.15M | 2.44M | -6.76M | 3.41M | -2.62M | -4.71M | -5.83M | -7.75M | -11.19M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 28.99K | 0 | 71.06K | 51.01K | 609.52K | 1.40M | 1.30M | 477.26K | 18.59K | 0 |
Stock-based compensation expense | 5.87K | 348.37K | 45.5K | 1 | 3.6K | 54.84K | 0 | 3.15K | 3K | 308.50K |
| Deferred income tax benefit | 5.87K | 348.37K | 45.5K | 1 | 3.6K | 54.84K | 0 | 3.15K | 3K | 308.50K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -94.87K | 254.27K | -41.08K | -109.99K | -34.1K | -71.18K | 29.76K | 83K | -83K | 0 |
Inventories | 0 | 0 | 0 | 4.58M | -3.99M | 620.30K | 0 | 3.24M | 802.66K | 0 |
Accounts payable | -5 | 875 | -62.70K | -18.98K | 18.48K | 11.42K | -415.19K | 254.99K | 214.90K | 22.54K |
Cash generated by operating activities | -693.14K | -173.91K | -606.92K | -1.13M | 18.64K | -481.79K | -1.57M | -1.89M | -1.67M | -11.01M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 25K | 495K | 0 | 49.85K | -5.74K | 0 | 0 | 0 |
Financing activities | ||||||||||
Common Stock Issued | 145.5K | 250K | 45.5K | 159 | 3K | 5.5K | 0 | 292.5K | 626.18K | 103.33K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -94.53K | -1.36M | -26.5K | 431.77K | -1.38M | 1.61M | -53.69K | 972.68K |
Cash used in financing activities | 572.81K | 243.75K | -94.03K | 1.36M | -26.5K | 431.77K | 1.32M | 2.13M | 1.65M | 11.05M |
Net Change In Cash | -120.32K | 69.83K | -675.95K | 727.16K | -7.85K | -164 | -261.95K | 245.15K | -13.79K | 38.62K |
Cash at end of period | 715 | 121.03K | 51.20K | 727.16K | 0 | 7.85K | 8.01K | 269.97K | 24.82K | 38.62K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |